AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
AstraZeneca is conducting a Phase 1b/2 clinical study titled ‘A Phase 1b/2 Study of GC012F (AZD0120), a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Relapsed/Refractory Multiple Myeloma.’ The study aims to evaluate the safety, tolerability, and efficacy of GC012F (AZD0120) in treating relapsed/refractory multiple myeloma, a significant area of unmet medical need.
The intervention being tested is GC012F (AZD0120), a biological CAR T-cell therapy designed to target CD19 and BCMA, which are proteins associated with multiple myeloma. The therapy is intended to improve treatment outcomes for patients with this challenging condition.
The study follows an interventional, open-label, single-group design, meaning all participants receive the same treatment without a placebo group. The primary purpose is to assess the treatment’s effectiveness and safety in a real-world setting.
The study began on July 20, 2023, with an estimated completion date set for August 5, 2025. These timelines are crucial for investors as they indicate when significant data readouts and potential market impacts might occur.
This clinical update could positively influence AstraZeneca’s stock performance by bolstering investor confidence in the company’s innovative pipeline. The success of GC012F (AZD0120) could also position AstraZeneca favorably against competitors in the oncology sector.
The study is ongoing, with further details available on the ClinicalTrials portal.